New cell therapy trial aims to halt debilitating MS progression
NCT ID NCT07477639
Summary
This early-stage clinical trial is testing an experimental cell therapy called TRX319 in adults with progressive forms of multiple sclerosis (MS). The main goals are to check if the treatment is safe, find the best dose, and see if it can slow or stop the worsening of MS symptoms. Participants will receive up to three infusions of TRX319 over one year and will undergo regular monitoring, including blood tests and MRI scans.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Kansas Medical Center
RECRUITINGKansas City, Kansas, 66160, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Washington University, St. Louis
RECRUITINGSt Louis, Missouri, 63110, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.